Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients.
To evaluate the potential role of the uPAR/uPA/PAI-1 system in HIV-induced blood-brain-barrier (BBB) disruption, CSF uPA-dependent plasminogen activation (PdPA) was analyzed by casein zymography, and CSF protein levels of all three molecules were measured by ELISA. CSF uPAR, but not uPA, PAI-1, or PdPA levels was significantly increased in neurologically compromised HIV+ patients. Only individual patients with severe AIDS dementia complex had increased levels of uPA (but not PAI-1) which fell upon initiation of antiretroviral therapy. The levels of all three molecules did not correlate with the CSF to serum albumin ratio suggesting not an important role in HIV-induced BBB disruption.
Sporer
B
B
Department of Neurology, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany. bsporer@nefo.med.uni-muenchen.de
Koedel
U
U
Popp
B
B
Paul
R
R
Pfister
H-W
HW
D015526:AIDS Dementia Complex / Q000134:cerebrospinal fluid / Q000201:enzymology / Q000276:immunology; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000134:cerebrospinal fluid* / Q000201:enzymology / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000134:cerebrospinal fluid*; D011956:Receptors, Cell Surface / Q000097:blood / Q000378:metabolism*; D055293:Receptors, Urokinase Plasminogen Activator; D012709:Serum Albumin / Q000134:cerebrospinal fluid; D012995:Solubility; D014568:Urokinase-Type Plasminogen Activator / Q000134:cerebrospinal fluid*; D019562:Viral Load
C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D012709:Serum Albumin; D014568:Urokinase-Type Plasminogen Activator